摘要:
A compound represented by formula (I) or a pharmacologically acceptable salt thereof, which can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues. (In the formula, A represents a 5- to 10-membered heteroaryl group, or a C6-10 aryl group; R1 and R2 independently represent H, OH, X, CN, NO2, a C1-4 haloalkyl group, a C1-6 alkyl group, or the like ; R3 represents H, a C1-5 alkyl group, a C6-10 aryl group, a C1-5 alkyl group, or a C1-4 haloalkyl group; and R4 represents H, X, a C1-3 alkyl group, a C1-4 haloalkyl group, OH, CN, NO2, or the like.)
摘要翻译:由式(I)表示的化合物或其药理学上可接受的盐,其可以抑制癌组织中的成纤维细胞生长因子受体(FGFR)家族激酶。 (式中,A表示5〜10元杂芳基或C6-10芳基; R1和R2独立地表示H,OH,X,CN,NO2,C1-4卤代烷基,C1- 6烷基等R 1和R 2一起形成(取代的)3-至10-元杂环基或(取代的)5至10元杂芳基>; R 3表示H,C 1-5烷基 ,C 6-10芳基,C 1-5烷基或C 1-4卤代烷基; R 4表示H,X,C 1-3烷基,C 1-4卤代烷基,OH,CN,NO 2, 等等)
摘要:
The object of the present invention is to provide a compound useful for the prevention and treatment of viral infectious diseases, and particularly liver diseases caused by HCV infection due to its having a high degree of replication inhibitory activity against HCV, its production method, an intermediate compound useful for its production and a pharmaceutical composition containing these compounds, and the present invention relates to a compound represented by the formula (I): (wherein A represents —(CH2)n—, etc.; B represents —(C═O)—, etc.; D represents —(CH2)m—R′, etc.; E represents a hydrogen atom, etc.; G represents —(CH2)p-J, etc.; bond Q represents a single bond or double bond; and R1, R2 and R3 may be the same or different and each represent a hydrogen atom, etc.), a prodrug thereof or a pharmaceutically acceptable salt thereof.
摘要:
The object of the present invention is to provide a compound useful for the prevention and treatment of viral infectious diseases, and particularly liver diseases caused by HCV infection due to its having a high degree of replication inhibitory activity against HCV, its production method, an intermediate compound useful for its production and a pharmaceutical composition containing these compounds, and the present invention relates to a compound represented by the formula (I): (wherein A represents —(CH2)n—, etc.; B represents —(C═O)—, etc.; D represents —(CH2)m—R′, etc.; E represents a hydrogen atom, etc.; G represents —(CH2)p-J, etc.; bond Q represents a single bond or double bond; and R1, R2 and R3 may be the same or different and each represent a hydrogen atom, etc.), a prodrug thereof or a pharmaceutically acceptable salt thereof.
摘要:
A compound represented by formula (I) or a pharmacologically acceptable salt thereof, which can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues. (In the formula, A represents a 5- to 10-membered heteroaryl group, or a C6-10 aryl group; R1 and R2 independently represent H, OH, X, CN, NO2, a C1-4 haloalkyl group, a C1-6 alkyl group, or the like ; R3 represents H, a C1-5 alkyl group, a C6-10 aryl group, a C1-5 alkyl group, or a C1-4 haloalkyl group; and R4 represents H, X, a C1-3 alkyl group, a C1-4 haloalkyl group, OH, CN, NO2, or the like.)
摘要翻译:由式(I)表示的化合物或其药理学上可接受的盐,其可以抑制癌组织中的成纤维细胞生长因子受体(FGFR)家族激酶。 (式中,A表示5〜10元杂芳基或C6-10芳基; R1和R2独立地表示H,OH,X,CN,NO2,C1-4卤代烷基,C1- 6烷基等R 1和R 2一起形成(取代的)3-至10-元杂环基或(取代的)5至10元杂芳基>; R 3表示H,C 1-5烷基 ,C 6-10芳基,C 1-5烷基或C 1-4卤代烷基; R 4表示H,X,C 1-3烷基,C 1-4卤代烷基,OH,CN,NO 2, 等等)
摘要:
The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof: wherein X, R1, R2, R3, R4, R5, R6, R7, L1, L2, and L3 are as defined in the specification.
摘要:
The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof: wherein X, R1, R2, R3, R4, R5, R6, R7, L1, L2, and L3 are as defined in the specification.